Sponsored Content | Webinar | Proton Therapy| October 13, 2016

WEBINAR: Economics of Establishing a Proton Therapy Center

This webinar is sponsored by IBA

IBA, proton therapy, economics of proton therapy, ROI of proton therapy, Proteus One

The webinar "Economics of Establishing a Proton Therapy Center," will help educate hospitals and oncology centers about the economics of building a proton therapy center and how it can potentially expand oncology services. IBA will take the mystery out of establishing a proton therapy center by walking attendees through the cost, staff, ROI and reimbursement management for a proton therapy center.

The webinar takes place Thursday, Nov. 3, 2016, 2-3 p.m. Eastern Time

Register for this webinar

 

Speakers

Joy Godby, BA, ROCC
Associate Director for Radiation Oncology
University of Texas MD Anderson Cancer Center
Houston, Texas

Godby manages the entire revenue cycle for radiation oncology (billing, coding, patient access, financial counseling, upfront appeals and back end appeals for all modalities). Her talk "Managing the Maze of Insurance authorization for Radiation Therapy" includes insights to reimbursement for oncology services.

 

Robert McElearney MBA
Vice President Strategic Accounts
IBA Proton Therapy North America

McElearney’s background in healthcare spans almost 20 years, working in every part of the country in senior positions of leadership in the healthcare industry. He led business development for the nation’s largest provider of mobile imaging services, directing its effort to expand into new business areas. McElearney provides overall new business leadership for IBA Inc. in partnering with health facilitates in developing a Proton Therapy Center.

 

Mary Elizabeth (Beth) Klein,
President, IBA Proton Therapy North America

Klein joined IBA in 2009, after more than 25 years with GE Healthcare. There she held various leadership roles including leading the nuclear medicine business and was the Americas commercial executive at TomoTherapy 2005-2007.

 

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer.s. The company is the worldwide technology leader in the field of proton therapy, which is considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single-room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1300 people worldwide, IBA has installed systems across the world. IBA is listed on the Pan-European stock exchange NYSE EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) More information can be found at: www.iba-worldwide.com

 

Register for this webinar

Related Content

targeted radiosurgery, stereotactic radiosurgery, whole-brain radiation, brain tumor metastases, Cureus, University of Missouri School of Medicine study
News | Radiation Therapy | February 16, 2017
University of Missouri (MU) School of Medicine researchers compared two common postsurgical therapies for metastatic...
ASTRO guideline, bone metastases, pallliative radiation therapy, gold standard
News | Radiation Therapy | February 14, 2017
February 14, 2017 — The American Society for Radiation Oncology (ASTRO) recently published an updated clinical guidel
Accuray, Radixact treatment delivery system, TomoTherapy, Shonin approval, Japan
News | Radiation Therapy | February 13, 2017
February 13, 2017 — Accuray Inc.
state of the proton therapy market entering 2017, proton therapy, radiation therapy, Robust Insight survey
News | Proton Therapy | February 10, 2017
Independent market research consultancy Robust Insight recently conveyed a survey commissioned by IBA on the state of...
EGFR mutant lung cancer, brain metastases, order of treatment, radiation therapy, EGFR-directed drugs, Journal of Clinical Oncology study
News | Lung Cancer | February 09, 2017
February 9, 2017 — A study published in the...
IBA, Dolphin Online Ready Patient QA and Monitoring solution, radiotherapy, North West Cancer Centre, Londonderry, Northern Ireland, first in U.K.
News | Radiation Therapy | February 07, 2017
IBA (Ion Beam Applications S.A.) recently announced the first clinical implementation of its Dolphin Online Ready...
Institut Curie, Onxeo, radiotherapy, immunotherapy, DNA repair inhibitors, AsiDNA, DBait
News | Radiation Therapy | February 06, 2017
Onxeo S.A. and the Institut Curie launched a series of studies on World Cancer Day (Feb. 4) aimed at investigating the...
radiotargeted therapy, SST2 antagonists, combat cancer, neuroendocrine tumors, NETs, Journal of Nuclear Medicine study

Comparative receptor autoradiography in various cancer types (A = HE staining) with I-125-JR11 (B+C) and I-125-Tyr3-octreotide (D+E). B and D are the respective total binding, C and E the respective non-specific binding. Bars = 1 mm.

I: Breast cancer. II: Renal cell cancer. III: Medullary thyroid cancer. IV: Non-Hodgkin lymphoma. V: Colon cancer. In cancers I-V, the sections were incubated with 30’000 cpm/100 μl of antagonist or agonist. Cancers I-IV show a much higher density of sst2 with the antagonist. The colon cancer V is negative. VI: Ileal NET, incubated with 10’000 cpm/100 μl of antagonist or agonist. Credit: Jean Claude Reubi, Institute of Pathology, University of Berne, Berne, Switzerland. 

News | Radiation Therapy | February 06, 2017
A study published in the February issue of The Journal of Nuclear Medicine demonstrates the potential of extending...
recurrent prostate cancer, hormone therapy, radiation therapy, Cedars-Sinai study, New England Journal of Medicine
News | Prostate Cancer | February 03, 2017
Adding hormonal therapy to radiation treatment can significantly improve the average long-term survival of men with...
Overlay Init